Table 1.
Baseline clinical characteristics of patients a
| Characteristics | TCZ users ( N = 46) | TNFi users ( N = 47) |
|---|---|---|
| Age (years) |
60 (28 to 75) |
55 (30 to 76) |
| Gender |
3 males, 43 females |
9 males, 38 females |
| Hb (g/dl) |
11.4 (8.9 to 14.4) |
11.8 (7.7 to 15.3) |
| MCV (fl) |
91.7 (72.4 to 101.5) |
94.2 (79.3 to 104.1) |
| Ferritin (ng/ml) |
81.4 (13.5 to 285.3) |
99.2 (9.8 to 398.2) |
| Fe (μg/dl) |
45.8 (9.0 to 120.0) |
56.5 (10.0 to 138.0) |
| CRP (mg/dl) |
3.37 (0.05 to 15.24) |
2.11 (0.04 to 9.16) |
| Hepcidin-25 (ng/ml) |
28.6 (0.3 to 123) |
30.5 (0.4 to 127.4) |
| Duration of RA (years) |
12.54 (1.6 to 43) |
8.16 (0.8 to 28) |
| SJC |
7.24 (0 to 24) |
5.59 (0 to 23) |
| TJC |
6.74 (0 to 23) |
6.54 (1 to 23) |
| RF (IU/ml) |
165.54 (0 to 1,166) |
144.24 (0 to 1,625) |
| DAS28 | 4.74 (2.00to 7.39) | 4.45 (2.33 to 7.23) |
aCRP, C-reactive protein; DAS28, Disease Activity Score in 28 joints; Fe, serum iron; ferritin, serum ferritin; Hb, hemoglobin; MCV, mean corpuscular volume; RF, rheumatoid factor; SJC, swollen joint count; TCZ, tocilizumab; TJC, tender joint count; TNFi, tumor necrosis factor α inhibitor. All data are means (ranges) unless otherwise specified.